Skip to main content
. 2023 Dec 14;25(4):193–200. doi: 10.1016/j.ccrj.2023.10.006

Table 2.

Characteristics of transfused and non-transfused patientsa.

All patients (n = 712) Transfused patients (n = 71) Patients not transfused (n = 641) P value
Age, years 60.4 (17.0) 60.3 (14.8) 60.4 (17.2) 0.95
Gender, male 448 (62.9) 46 (64.8) 402 (62.7) 0.73
BMI, kg/m2 29.8 (9.8) 28.1 (10.2) 30.0 (9.7) 0.15
APACHE II score 17 (8) 19 (7) 16.7 (7.5) 0.02
ICU admission source 0.06
 Elective surgery 136 (19.1) 17 (23.9) 119 (18.6)
 Emergency surgery 106 (14.9) 12 (16.9) 94 (14.7)
 Emergency department 222 (31.2) 15 (21.1) 207 (32.3)
 Hospital ward 163 (22.9) 19 (26.8) 144 (22.5)
 Transfer from another ICU 38 (5.3) 7 (9.9) 31 (4.8)
 Transfer from another hospital (not ICU) 47 (6.6) 1 (1.4) 46 (7.2)
Primary ICU non-operative diagnosis 0.10
 Cardiovascular 84 (18.2) 9 (22.5) 75 (17.8)
 Respiratory 97 (21.0) 6 (15.0) 91 (21.6)
 Gastrointestinal 35 (7.6) 6 (15.0) 29 (6.9)
 Neurological 68 (14.8) 2 (5.0) 66 (15.7)
 Sepsis 74 (16.1) 5 (12.5) 69 (16.4)
 Trauma and burns 45 (9.8) 3 (7.5) 42 (10.0)
 Metabolic 26 (5.6) 5 (12.5) 21 (5.0)
 Haematological 8 (1.7) 2 (5.0) 6 (1.4)
 Renal/genitourinary 11 (2.4) 0 (0.0) 11 (2.6)
 Gynaecological 3 (0.7) 2 (5.0) 66 (15.7)
 Musculoskeletal/skin 6 (1.3) 1 (2.5) 5 (1.2)
 Other medical 4 (0.9) 1 (2.5) 3 (0.7)
Post-operative admission 251 (35.3) 31 (43.7) 220 (34.3) 0.12
Primary ICU operative diagnosis 0.33
 Cardiovascular 55 (21.9) 8 (25.8) 47 (21.4)
 Respiratory and ENT 19 (7.6) 2 (6.5) 17 (7.7)
 Gastrointestinal 55 (21.9) 8 (25.8) 47 (21.4)
 Neurological 31 (12.4) 0 (0.0) 31 (14.1)
 Trauma and burns 25 (10.0) 3 (9.7) 22 (10.0)
 Renal/genitourinary 9 (3.6) 1 (3.2) 8 (3.6)
 Gynaecological 6 (2.4) 0 (0.0) 6 (2.7)
 Musculoskeletal/skin 14 (5.6) 1 (3.2) 13 (5.9)
Invasive mechanical ventilation 274 (38.5) 35 (49.3) 239 (37.3) <0.05
Respiratory support 210 (29.5) 20 (28.2) 190 (29.6)
ARDS 10 (1.4) 2 (2.8) 8 (1.3) 0.29
Injury by blunt or penetrating trauma 78 (11.0) 7 (9.9) 71 (11.1) 0.76
Defined focus of infection 247 (34.7) 29 (40.9) 218 (34.0) 0.25
SIRS 379 (53.2) 50 (70.4) 329 (51.3) <0.01
Vasopressors to maintain MAP 235 (33.0) 38 (53.5) 197 (30.7) <0.01
Chronic health conditions
 Cirrhosis and portal hypertension or previous hepatic failure 23 (3.2) 5 (7.0) 18 (2.8) 0.06
 NYHA IV 22 (3.1) 4 (5.6) 18 (2.8) 0.19
 Chronic respiratory disease 55 (7.7) 4 (5.6) 51 (8.0) 0.49
 Immunocompromised 91 (12.8) 11 (15.5) 80 (12.5) 0.47
 Medications
 Anti-platelet medication prior to ICU admission 189 (27.5) 16 (23.9) 173 (27.9) 0.49
 Anti-platelet medication during ICU admission 198 (27.9) 22 (31.0) 176 (27.5) 0.53
 Anti-coagulation medication prior to ICU admission 172 (25.3) 20 (29.9) 152 (24.8) 0.36
 Anti-coagulation medication during ICU admission 482 (67.9) 44 (62.0) 438 (68.5) 0.26

APACHE, acute physiology and chronic health evaluation; ARDS, acute respiratory distress syndrome; BMI, body mass index; ENT, ear, nose and throat; ICU, intensive care unit; MAP, mean arterial pressure; NYHA, New York Heart Association; SIRS, systemic inflammatory response syndrome.

a

Results are reported in mean (SD) for continuous variables and n (%) for categorical variables.